Related Experiment Video
Updated: Aug 14, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas
Abstract:
Dysregulation of apoptosis plays an important role in tumour progression and resistance to chemotherapy. The X-linked inhibitor of apoptosis (XIAP) is considered to be the most potent caspase inhibitor of all known inhibitor of apoptosis-family members. Only recently, an antagonist of XIAP has been identified, termed Smac/DIABLO. To explore the relevance of antiapoptotic XIAP and proapoptotic Smac/DIABLO for tumour progression in renal cell carcinomas (RCCs), we analysed XIAP and Smac/DIABLO mRNA and protein expression in the primary tumour tissue from 66 RCCs of all major histological types by quantitative real-time PCR, Western blot and ELISA. X-linked inhibitor of apoptosis and Smac/DIABLO mRNA expression was found in all RCCs. Importantly, the relative XIAP mRNA expression levels significantly increased from early (pT1) to advanced (pT3) tumour stages (P=0.0002) and also with tumour dedifferentiation (P=0.04). Western blot analysis confirmed the tumour stage-dependent increase of XIAP expression on the protein level. In contrast, mRNA and protein expression levels of Smac/DIABLO did not significantly change between early and advanced tumour stages or between low and high tumour grades. Consequently, the mRNA expression ratio between antiapoptotic XIAP and proapoptotic Smac/DIABLO markedly increased during progression from early (pT1) to advanced (pT3) tumour stages. Moreover, RCCs confined within the organ capsule (pT1 and pT2) exhibited a significantly lower XIAP to Smac/DIABLO expression ratio when compared with RCCs infiltrating beyond the kidney (pT3; P=0.01). Thus, our investigation demonstrates that the delicate balance between XIAP and Smac/DIABLO expression is gradually disturbed during progression of RCCs, resulting in a relative increase of antiapoptotic XIAP over proapoptotic Smac/DIABLO, thereby probably contributing to the marked apoptosis resistance of RCC.
Insights
Dysregulation of apoptosis in renal cell carcinoma (RCC) is linked to increased X-linked inhibitor of apoptosis (XIAP) and decreased Smac/DIABLO. This imbalance promotes tumor progression and chemoresistance in RCC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Research
Background:
- Apoptosis dysregulation is key in tumor progression and chemotherapy resistance.
- X-linked inhibitor of apoptosis (XIAP) is a potent caspase inhibitor.
- Smac/DIABLO is a recently identified XIAP antagonist.
Purpose of the Study:
- To investigate the roles of XIAP and Smac/DIABLO in renal cell carcinoma (RCC) progression.
- To analyze XIAP and Smac/DIABLO mRNA and protein expression in RCC tissues.
Main Methods:
- Quantitative real-time PCR for mRNA expression.
- Western blot and ELISA for protein expression.
- Analysis of 66 primary RCC tissues across major histological types.
Main Results:
- XIAP mRNA and protein expression significantly increased with RCC tumor stage and dedifferentiation.
- Smac/DIABLO expression showed no significant changes with tumor stage or grade.
- The XIAP to Smac/DIABLO expression ratio increased significantly in advanced RCC stages (pT3) compared to early stages (pT1).
Conclusions:
- The balance between XIAP and Smac/DIABLO is disturbed in RCC progression.
- Increased XIAP relative to Smac/DIABLO likely contributes to apoptosis resistance in RCC.
- This finding has implications for understanding RCC pathogenesis and treatment resistance.

